{
  "Variants Include": [
    {
      "Gene": "SNCA",
      "variants": [
        {
          "HGVS": "NM_000345.4:c.88G>C",
          "cDNA Change": {
            "transcript": "NM_000345.4",
            "ref": "G",
            "alt": "C",
            "position": "88"
          },
          "Protein Change": {
            "ref": "A",
            "alt": "P",
            "position": "30"
          },
          "Description in input context": "A30P, a mutation associated with early-onset familial Parkinson's disease."
        },
        {
          "HGVS": "NM_000345.4:c.157G>A",
          "cDNA Change": {
            "transcript": "NM_000345.4",
            "ref": "G",
            "alt": "A",
            "position": "157"
          },
          "Protein Change": {
            "ref": "A",
            "alt": "T",
            "position": "53"
          },
          "Description in input context": "A53T, a mutation associated with early-onset familial Parkinson's disease, showing enhanced inhibition of PLD2."
        }
      ]
    }
  ],
  "Described Disease": {
    "Described Disease": "Parkinson's Disease",
    "MONDO": "MONDO:0005180"
  },
  "Experiment Method": [
    {
      "Assay Method": "PLD2 Inhibition Assay",
      "Material used": {
        "Material Source": "Cell line",
        "Material Name": "Sf9 cells",
        "Description": "hPLD2 was expressed in Sf9 cells using a baculovirus construct and purified for the assay."
      },
      "Readout type": "Quantitative",
      "Readout description": [
        {
          "Variant": "NM_000345.4:c.88G>C",
          "Conclusion": "Normal",
          "Molecular Effect": "No Effect",
          "Result Description": "A30P inhibition of PLD2 was not different from wild-type a-synuclein."
        },
        {
          "Variant": "NM_000345.4:c.157G>A",
          "Conclusion": "Abnormal",
          "Molecular Effect": "gain-of-function",
          "Result Description": "A53T mutant showed greater inhibitory effect on PLD2 compared to wild-type a-synuclein."
        }
      ],
      "Biological replicates": {
        "Biological replicates": "Yes",
        "Description": "Means and standard deviations for three or four separate experiments are shown in the results."
      },
      "Technical replicates": {
        "Technical replicates": "N.D.",
        "Description": "No specific mention of technical replicates in the literature."
      },
      "Basic positive control": {
        "Basic positive control": "Yes",
        "Description": "Wild-type a-synuclein was used as a reference for comparison with mutants."
      },
      "Basic negative control": {
        "Basic negative control": "Yes",
        "Description": "hPLD2 activity was measured in the absence of a-synuclein as a baseline control."
      },
      "Validation controls P/LP": {
        "Validation controls P/LP": "Yes",
        "Counts": "2"
      },
      "Validation controls B/LB": {
        "Validation controls B/LB": "No",
        "Counts": "0"
      },
      "Statistical analysis method": {
        "Statistical analysis method": "Analysis of covariates (ANCOVA) using the General Linear Model to compare slopes between proteins, performed with SAS software."
      },
      "Threshold for normal readout": {
        "Threshold for normal readout": "Inhibition similar to wild-type a-synuclein, with slope of inhibitory curve not significantly different from wild-type.",
        "Source": "Custom"
      },
      "Threshold for abnormal readout": {
        "Threshold for abnormal readout": "Significant deviation in inhibitory curve slope compared to wild-type a-synuclein, indicating enhanced or reduced inhibition.",
        "Source": "Custom"
      },
      "Approved assay": {
        "Approved assay": "Yes"
      }
    },
    {
      "Assay Method": "Circular Dichroism Spectroscopy",
      "Material used": {
        "Material Source": "Recombinant Protein",
        "Material Name": "Recombinant a-synuclein mutants",
        "Description": "CD spectra were collected for hAS and mutants DYD and S129E in the presence of lipid vesicles."
      },
      "Readout type": "Quantitative",
      "Readout description": [
        {
          "Variant": "NM_000345.4:c.88G>C",
          "Conclusion": "N.D.",
          "Molecular Effect": "N.D.",
          "Result Description": "No specific results for A30P in circular dichroism spectroscopy mentioned in the literature."
        },
        {
          "Variant": "NM_000345.4:c.157G>A",
          "Conclusion": "N.D.",
          "Molecular Effect": "N.D.",
          "Result Description": "No specific results for A53T in circular dichroism spectroscopy mentioned in the literature."
        }
      ],
      "Biological replicates": {
        "Biological replicates": "N.D.",
        "Description": "No specific mention of biological replicates for circular dichroism spectroscopy in the literature."
      },
      "Technical replicates": {
        "Technical replicates": "N.D.",
        "Description": "No specific mention of technical replicates for circular dichroism spectroscopy in the literature."
      },
      "Basic positive control": {
        "Basic positive control": "Yes",
        "Description": "Wild-type hAS was used as a reference for comparison with mutants."
      },
      "Basic negative control": {
        "Basic negative control": "N.D.",
        "Description": "No specific negative control mentioned for circular dichroism spectroscopy."
      },
      "Validation controls P/LP": {
        "Validation controls P/LP": "No",
        "Counts": "0"
      },
      "Validation controls B/LB": {
        "Validation controls B/LB": "No",
        "Counts": "0"
      },
      "Statistical analysis method": {
        "Statistical analysis method": "N.D."
      },
      "Threshold for normal readout": {
        "Threshold for normal readout": "a-helix content similar to wild-type hAS (approximately 77%) in the presence of lipid vesicles.",
        "Source": "Custom"
      },
      "Threshold for abnormal readout": {
        "Threshold for abnormal readout": "Significant reduction in a-helix content compared to wild-type hAS in the presence of lipid vesicles.",
        "Source": "Custom"
      },
      "Approved assay": {
        "Approved assay": "Yes"
      }
    }
  ]
}